Researchers tie age‑47 insulin levels to earlier, longer‑lasting vasomotor symptoms in women
A simple blood test in a woman’s late 40s may flag who is headed for earlier and longer‑lasting hot flashes, night sweats and cold sweats, according to research in The Journal of Clinical Endocrinology & Metabolism.
According to the study, higher fasting insulin at age 47 predicted:
-
earlier onset of hot flashes and night sweats, and
-
longer duration of hot flashes and cold sweats across the menopausal transition.
Crucially, the authors report that insulin remained a significant predictor of hot flashes even after they adjusted for body mass index (BMI), fasting glucose, race/ethnicity, income and smoking.
When insulin, BMI and fasting glucose were all in the model, only insulin still had a statistically significant association with hot flash risk.
The researchers drew on 10‑year data from 704 women in the Study of Women’s Health Across the Nation (SWAN), a large US cohort that tracks women from their early‑ to mid‑40s through menopause.
They focused on metabolic measures at age 47—fasting insulin, fasting glucose and BMI—and related these to the timing and duration of menopausal symptoms and to hormone changes over time.
The symptoms in question—hot flashes, night sweats and cold sweats—are vasomotor symptoms that affect about three‑quarters of women during menopause. They can begin roughly two years before the final menstrual period and continue for up to 10 years afterwards.
The paper notes that these episodes can disrupt work and daily functioning, for example when a woman has to present at a board meeting while flushing and overheating, or manage night shifts as a police officer or surgeon after repeated sleep disruption from drenching sweats.
The study also reports that BMI at age 47 tracked with vasomotor symptoms, but in a different way and with weaker effects once the authors controlled for other variables.
Higher BMI predicted earlier onset of hot flashes and night sweats and a longer duration of cold sweats, but lost significance for some outcomes after adjustment.
Hormone patterns showed another split between insulin and BMI.
According to the article, women with higher BMI at 47 had a slower decline in estradiol and a slower rise in follicle‑stimulating hormone (FSH) across the menopausal transition.
Higher insulin, by contrast, was tied to a steeper increase in testosterone, a more “hyperandrogenic” pattern that earlier research has linked to worse cardiometabolic outcomes and a higher risk of type 2 diabetes.
The authors situate these findings in a broader body of work that links metabolic health and menopause.
Prior studies they cite show that women with higher body fat report more frequent and severe vasomotor symptoms, especially early in the transition, and that insulin resistance—as estimated by HOMA‑IR—is associated with more hot flashes and night sweats.
Other work they reference connects more severe vasomotor symptoms to a higher subsequent risk of type 2 diabetes.
Taken together, the new analysis suggests two things, as per The Journal of Clinical Endocrinology & Metabolism:
-
midlife metabolic health shapes not just long‑term cardiometabolic risk but also the timing and burden of menopausal symptoms, and
-
fasting insulin may be a more sensitive signal than BMI for some key outcomes, especially hot flashes and androgen shifts.
The paper also notes a practical angle: while reversing obesity is difficult and influenced by social and biological factors, insulin levels can respond more quickly to lifestyle interventions.
The authors point to evidence that aerobic and resistance exercise can lower insulin and improve insulin sensitivity even without weight loss, and that declines in insulin often appear before the scale moves.
At the same time, they are clear about limitations.
Symptom data came from annual recall over a two‑week window, which blurs the exact timing of onset.
Hormones and insulin were measured only once a year, and the dataset captured fasting insulin but not post‑meal responses.
Medication information was incomplete beyond reported use of insulin or pills for high blood sugar.
Even with those caveats, the study concludes that fasting insulin and BMI in the late 40s relate in distinct, complementary ways to both menopausal symptoms and hormone trajectories.
According to the journal, insulin stands out as a stronger independent predictor of hot flashes and testosterone changes than BMI or fasting glucose once all three are considered together, highlighting hyperinsulinaemia as a potential early marker of which women may face a heavier vasomotor symptom burden.
